STOCK TITAN

Minerva Neurosciences (NERV) grants director 50,000 stock options at $4.68

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Minerva Neurosciences director Fouzia Laghrissi-Thode received a stock option grant covering 50,000 shares of common stock. The option has an exercise price of $4.68 per share and expires on June 2, 2036. It vests in four equal quarterly installments, with the first 12,500 shares vesting three months after June 3, 2026 and additional 12,500-share tranches vesting every three months thereafter, subject to her continued service as a non-employee director. This filing reports a compensation-related award rather than any open-market buying or selling of shares.

Positive

  • None.

Negative

  • None.
Insider Laghrissi-Thode Fouzia
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 50,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 50,000 options Stock Option (right to buy) granted to director
Exercise price $4.68 per share Conversion or exercise price of stock option
Expiration date June 2, 2036 Option expiry for director grant
Underlying shares 50,000 shares Common Stock underlying granted option
Post-grant derivative holdings 50,000 options Total derivative securities following transaction
Vesting installments 4 quarterly tranches Equal installments every three months after June 3, 2026
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 4.6800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"The shares subject to this option vest in four equal quarterly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
expiration date financial
"expiration_date: 2036-06-02T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
non-employee director financial
"subject to the continued service of the Reporting Person as a non-employee director"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Laghrissi-Thode Fouzia

(Last)(First)(Middle)
C/O MINERVA NEUROSCIENCES, INC.,
1500 DISTRICT AVENUE

(Street)
BURLINGTON MASSACHUSETTS 01803

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Minerva Neurosciences, Inc. [ NERV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$4.6806/03/2026A50,000 (1)06/02/2036Common Stock50,000$050,000D
Explanation of Responses:
1. The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 3, 2026 and an additional 1/4 vesting every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.
/s/ Frederick Ahlholm, Attorney-in-Fact06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Fouzia Laghrissi-Thode receive in this Minerva Neurosciences (NERV) Form 4?

She received a stock option grant for 50,000 shares of common stock. The options are a compensation-related award, not an open-market purchase, and give her the right to buy shares at a fixed price if they vest.

What is the exercise price of the new Minerva Neurosciences (NERV) stock options?

The stock options have an exercise price of $4.68 per share. This means she can buy Minerva Neurosciences common stock at $4.68 for each option that vests and is exercised before expiration.

How do the 50,000 Minerva Neurosciences (NERV) options vest for Fouzia Laghrissi-Thode?

The 50,000 options vest in four equal quarterly installments of 12,500 shares each. Vesting starts three months after June 3, 2026, with additional tranches vesting every three months, contingent on her continued service as a non-employee director.

When do Fouzia Laghrissi-Thode’s Minerva Neurosciences (NERV) options expire?

The stock options expire on June 2, 2036. She must exercise vested options on or before that expiration date; any unexercised options after that date will no longer be exercisable.

Did Fouzia Laghrissi-Thode buy or sell Minerva Neurosciences (NERV) shares in the market?

No, this filing reports a grant of stock options as compensation. It does not show any open-market buying or selling of Minerva Neurosciences common stock by Fouzia Laghrissi-Thode on the reported date.